Angiotensin Blockers Move To First-Line In ACC/AHA Heart Failure Guidelines
Executive Summary
Angiotensin receptor blockers can be considered as a first-line treatment in heart failure patients with reduced left ventricular ejection fraction, the updated American College of Cardiology/American Heart Association heart failure guidelines indicate
You may also be interested in...
FDA Broadens Diovan Heart Failure Indication Based On Atacand Clinical Data
FDA has cleared Novartis' angiotensin II receptor blocker Diovan (valsartan) for first-line use in the treatment of heart failure using data generated by AstraZeneca for its ARB Atacand (candesartan)
BiDil Survival Benefit Precludes Need For Component Efficacy Evaluation
NitroMed's BiDil demonstration of a survival benefit in African-Americans with heart failure makes moot an investigation into the safety and efficacy of the combination drug's individual components, an FDA advisory committee agreed
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients